The latest price target for Finch Therapeutics Gr (OTCPK:FNCH) was reported by HC Wainwright & Co. on May 12, 2023. The analyst firm set a price target for $7.00 expecting FNCH to fall to within 12 months (a possible -39.81% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Finch Therapeutics Gr (OTCPK:FNCH) was provided by HC Wainwright & Co., and Finch Therapeutics Gr reiterated their buy rating.

There is no last upgrade for Finch Therapeutics Gr

There is no last downgrade for Finch Therapeutics Gr.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Finch Therapeutics Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Finch Therapeutics Gr was filed on May 12, 2023 so you should expect the next rating to be made available sometime around May 12, 2024.

While ratings are subjective and will change, the latest Finch Therapeutics Gr (FNCH) rating was a reiterated with a price target of $7.00 to $7.00. The current price Finch Therapeutics Gr (FNCH) is trading at is $11.63, which is out of the analyst’s predicted range.